West Pharmaceutical Services (NYSE:WST) Coverage Initiated at Rothschild & Co Redburn

Key Points

• Analysts at Rothschild & Co Redburn have initiated coverage on West Pharmaceutical Services (NYSE:WST), assigning a "buy" rating with a price target of $311.00, indicating a potential upside of 22.68% from its previous close.
• The company's recent earnings report revealed an EPS of $1.84, surpassing estimates and showing a 9.2% revenue increase year-over-year.
• West Pharmaceutical Services has a consensus rating of "Moderate Buy" from analysts, with an average price target of $319.50.

Equities research analysts at Rothschild & Co Redburn initiated coverage on shares of West Pharmaceutical Services (NYSE:WST - Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The firm set a "buy" rating and a $311.00 price target on the medical instruments supplier's stock. Rothschild & Co Redburn's price target would suggest a potential upside of 23.23% from the company's previous close.

A number of other research analysts have also issued reports on WST. Barclays assumed coverage on West Pharmaceutical Services in a report on Tuesday, June 24th. They issued an "equal weight" rating and a $245.00 target price for the company. Wall Street Zen raised shares of West Pharmaceutical Services from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. UBS Group increased their price target on West Pharmaceutical Services from $285.00 to $320.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Evercore ISI upped their price objective on shares of West Pharmaceutical Services from $275.00 to $350.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Finally, Citigroup reissued a "buy" rating on shares of West Pharmaceutical Services in a report on Thursday, May 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, West Pharmaceutical Services has an average rating of "Buy" and an average price target of $318.56.

West Pharmaceutical Services Stock Performance

Shares of WST stock traded down $2.61 during trading hours on Monday, hitting $252.37. The company's stock had a trading volume of 220,668 shares, compared to its average volume of 812,864. The stock has a market cap of $18.15 billion, a PE ratio of 37.78, a price-to-earnings-growth ratio of 4.55 and a beta of 1.05. West Pharmaceutical Services has a 12-month low of $187.43 and a 12-month high of $352.33. The company has a 50 day moving average of $243.64 and a 200 day moving average of $226.24. The company has a current ratio of 2.78, a quick ratio of 2.08 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The medical instruments supplier reported $1.84 EPS for the quarter, topping analysts' consensus estimates of $1.51 by $0.33. The business had revenue of $766.50 million for the quarter, compared to analysts' expectations of $725.11 million. West Pharmaceutical Services had a net margin of 16.48% and a return on equity of 18.43%. The business's revenue was up 9.2% on a year-over-year basis. During the same quarter last year, the company earned $1.52 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 6.650-6.850 EPS. On average, sell-side analysts forecast that West Pharmaceutical Services will post 6.62 EPS for the current fiscal year.

Hedge Funds Weigh In On West Pharmaceutical Services

A number of institutional investors have recently made changes to their positions in WST. Zions Bancorporation National Association UT bought a new position in shares of West Pharmaceutical Services in the 1st quarter valued at about $25,000. CYBER HORNET ETFs LLC acquired a new stake in shares of West Pharmaceutical Services in the second quarter valued at approximately $25,000. Quarry LP acquired a new position in shares of West Pharmaceutical Services during the 1st quarter worth approximately $27,000. Vermillion & White Wealth Management Group LLC grew its stake in shares of West Pharmaceutical Services by 193.9% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier's stock valued at $32,000 after acquiring an additional 95 shares in the last quarter. Finally, First Horizon Advisors Inc. boosted its position in shares of West Pharmaceutical Services by 85.0% during the 1st quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier's stock worth $41,000 after acquiring an additional 85 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.